Status:
ACTIVE_NOT_RECRUITING
The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
Lead Sponsor:
Rose Research Center, LLC
Collaborating Sponsors:
Foundation for a Smoke Free World INC
Conditions:
Smoking Cessation
Eligibility:
All Genders
21-65 years
Phase:
PHASE3
Brief Summary
This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs)...
Eligibility Criteria
Inclusion
- Has signed the ICF and is able to read and understand the information provided in the ICF.
- Is 21 to 65 years of age (inclusive) at screening.
- Smokes at least 10 commercially available cigarettes per day (no brand restrictions), for the last 12 months.
- Has an expired air CO reading of at least 10 ppm at screening.
- Is interested in switching to an electronic cigarette.
- Is willing and able to comply with the requirements of the study.
- Owns a smartphone with text message and data capabilities compatible with necessary surveys.
Exclusion
- Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, ECG, concomitant medications and medical history).
- Has a PHQ-9 score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening.
- Has plans to use an FDA-approved smoking cessation product during the study.
- Has high blood pressure (systolic \> 150 mmHg or diastolic \>95 mmHg) at screening.
- Has body mass index (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2.
- Has coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.
- Has received psychotherapy or behavioral treatments potentially impacting symptoms of depression, anxiety, or nicotine withdrawal within 30 days of screening, or during the study.
- Is taking antidepressants, psychoactive medications (e.g. antipsychotics, benzodiazepines, hypnotics) or medications that prolong QTc.
- Has used any of these products in the past 30 days:
- Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, methamphetamines, or opiates);
- Experimental (investigational) drugs that are unknown to participant;
- Chronic opiate use.
- Has used smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black \& Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.
- Has a plan to use an FDA-approved quit-smoking treatment in the next 30 days.
- Is pregnant or nursing (by self-report) or has a positive pregnancy test.
- Enrollment requirements met.
Key Trial Info
Start Date :
December 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 20 2025
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05205811
Start Date
December 14 2021
End Date
October 20 2025
Last Update
August 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Rose Research Center
Charlotte, North Carolina, United States, 28262
2
Rose Research Center
Raleigh, North Carolina, United States, 27617